Close
Update on the CENTAUR trial: open label extension data

Update on the CENTAUR trial: open label extension data

Reading Time: 3 minutes A centaur was a creature from Greek mythology which was half-man and half-horse. Despite such an unusual appearance such a combination could have its advantages. It seems that another combination may hold promise in the future for people with ALS/MND (see our previous blog). The CENTAUR clinical trial, which tested a combination of two compounds,…

Encouraging NP001 clinical trial results for MND

Reading Time: 3 minutes Promising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested that NP001 is safe, well tolerated and could be beneficial for MND. Following these encouraging results, Neuraltus plan to begin a larger, Phase III trial of NP001 in the second half…